Crossmark

Landscape analysis of adverse events and dose intensity for FDA approved oncology small molecules

Published Online: 2025-01-04

Published Print: 2025-12

Authors

Collins, Keagan P.

Yin, Donghua

Pithavala, Yazdi K.

Mittapalli, Rajendar K.
License Information

Text and Data Mining valid from 2025-01-04

Version of Record valid from 2025-01-04
More Information

Article History

Received: 10 June 2024

Accepted: 13 November 2024

First Online: 4 January 2025

Declarations

:

: KPC, DY, YKP, RKM are employees of Pfizer and hold Pfizer stock or stock options.

Document is current